Literature DB >> 12185452

TGF-beta(1) gene modified immature dendritic cells exhibit enhanced tolerogenicity but induce allograft fibrosis in vivo.

Wenji Sun1, Quanxing Wang, Lihuang Zhang, Jianping Pan, Min Zhang, Guohua Lu, Hangping Yao, Jianli Wang, Xuetao Cao.   

Abstract

Administration of donor-derived immature dendritic cells (DC) can prolong the survival of MHC-mismatched cardiac allografts. Genetic modification of DC by immunosuppressive molecules can enhance their potential tolerogenicity. In this study bone marrow derived immature DC were genetically modified by transforming growth factor (TGF) beta1 by recombinant Ad. TGF-beta(1) gene modified immature DC (TGF-beta-DC) displayed a characteristic phenotype of immature DC, decreased ability to secrete interleukin 12, and reduced allostimulatory ability. TGF-beta-DC induced alloantigen-specific T cell hyporesponsiveness in vitro and in vivo, and Th2 cytokine polarization. mRNA expression of donor MHC class II (Ia(b)) and human TGF-beta(1) was detected in spleen and lymph nodes of the allogeneic recipients for 3 weeks after TGF-beta-DC infusion, indicating that microchimerism of TGF-beta-DC is exhibited in allogeneic recipients. In this murine cervical heterotopic heart transplantation model, the survival of the allograft in recipients intravenously infused with TGF-beta-DC 7 days before transplantation was greatly prolonged, and about 67% of cardiac grafts survived more than 40 days. Histological analysis of the allografts showed that the normal myocardial architecture was well preserved, accompanied by very little necrotic cells, but interstitial fibrosis replaced myocytes, and moderate collagen suffused the whole cardiac allograft in the recipients infused with TGF-beta-DC. mRNA expression of type III procollagen was markedly increased in the allografts of the recipients infused with TGF-beta-DC. Our results suggest that infusion of TGF-beta(1) gene modified immature DC prolongs the survival of the allograft through the effective induction of donor-specific T cell hyporesponsiveness. However, TGF-beta(1) expressed by gene modified immature DC can cause the fibrosis of the allografts, which may limit the application of this approach in the allograft transplantation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12185452     DOI: 10.1007/s00109-002-0346-2

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  8 in total

Review 1.  Immunoregulation of dendritic cells.

Authors:  Mark A Wallet; Pradip Sen; Roland Tisch
Journal:  Clin Med Res       Date:  2005-08

2.  Apoptotic cell administration enhances pancreatic islet engraftment by induction of regulatory T cells and tolerogenic dendritic cells.

Authors:  Cong Wu; Yi Zhang; Yingming Jiang; Quanxing Wang; Yao Long; Chunmei Wang; Xuetao Cao; Guoyou Chen
Journal:  Cell Mol Immunol       Date:  2013-07-22       Impact factor: 11.530

3.  mir-155 regulates cardiac allograft rejection by targing the expression of suppressor of cytokine signaling-1 (DOCS1) in dendritic cells.

Authors:  Yi Gao; Fang Liu; Qiwei Zhou; Meng Guo; Mingjian Zhang; Wenyuan Guo; Liming Wang; Liping Hu; Chaozhou Hu; Yongzhao Shi; Yushan Liu; Quanxing Wang
Journal:  Int J Clin Exp Med       Date:  2014-11-15

4.  TGF-beta1 gene-modified, immature dendritic cells delay the development of inflammatory bowel disease by inducing CD4(+)Foxp3(+) regulatory T cells.

Authors:  Zhijian Cai; Wei Zhang; Min Li; Yinpu Yue; Fei Yang; Lei Yu; Xuetao Cao; Jianli Wang
Journal:  Cell Mol Immunol       Date:  2010-01       Impact factor: 11.530

5.  Trypanosoma cruzi induces regulatory dendritic cells in vitro.

Authors:  Carolina Verónica Poncini; Catalina Dirney Alba Soto; Estela Batalla; Maria Elisa Solana; Stella Maris González Cappa
Journal:  Infect Immun       Date:  2008-03-17       Impact factor: 3.441

6.  Effective induction of immune tolerance by portal venous infusion with IL-10 gene-modified immature dendritic cells leading to prolongation of allograft survival.

Authors:  Ming Zhang; Quanxing Wang; Yushan Liu; Yanping Sun; Guoshan Ding; Zhiren Fu; Zhilian Min; Youhua Zhu; Xuetao Cao
Journal:  J Mol Med (Berl)       Date:  2004-04       Impact factor: 4.599

Review 7.  Metabolism Is Central to Tolerogenic Dendritic Cell Function.

Authors:  Wen Jing Sim; Patricia Jennifer Ahl; John Edward Connolly
Journal:  Mediators Inflamm       Date:  2016-02-11       Impact factor: 4.711

8.  LPS activation is required for migratory activity and antigen presentation by tolerogenic dendritic cells.

Authors:  Amy E Anderson; David J Swan; Bethan L Sayers; Rachel A Harry; Angela M Patterson; Alexei von Delwig; John H Robinson; John D Isaacs; Catharien M U Hilkens
Journal:  J Leukoc Biol       Date:  2008-11-06       Impact factor: 4.962

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.